M. Hallek, K. Fischer, G. Fingerle-rowson, A. M. Fink, R. Busch et al., Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Lancet Lond Engl, vol.376, pp.1164-74, 2010.

B. Eichhorst, T. Robak, E. Montserrat, P. Ghia, P. Hillmen et al., Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol, vol.26, issue.5, pp.78-84, 2015.

D. Rossi, L. Terzi-di-bergamo, D. Paoli, L. Cerri, M. Ghilardi et al., Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia, Blood, vol.126, pp.1921-1925, 2015.

P. A. Thompson, C. S. Tam, S. M. O'brien, W. G. Wierda, F. Stingo et al., Fludarabine, cyclophosphamide, and rituximab treatment achieves longterm disease-free survival in IGHV-mutated chronic lymphocytic leukemia, Blood, vol.127, pp.303-312, 2016.

K. Fischer, J. Bahlo, A. M. Fink, V. Goede, C. D. Herling et al., Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial, Blood, vol.127, pp.208-223, 2016.

C. Chai-adisaksopha and J. R. Brown, FCR achieves long-term durable remissions in patients with IGHV-mutated CLL, Blood, vol.130, pp.2278-82, 2017.

S. Böttcher, M. Ritgen, K. Fischer, S. Stilgenbauer, R. M. Busch et al., Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.30, pp.980-988, 2012.

G. Kovacs, S. Robrecht, A. M. Fink, J. Bahlo, P. Cramer et al., Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL study group, J Clin Oncol Off J Am Soc Clin Oncol, 2016.

M. Kwok, A. C. Rawstron, A. Varghese, P. Evans, S. O'connor et al., Minimal residual disease is an independent predictor for 10-year survival in CLL, Blood, vol.128, pp.2770-2773, 2016.

V. Goede, K. Fischer, R. Busch, A. Engelke, B. Eichhorst et al., Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions, N Engl J Med, vol.370, pp.1101-1111, 2014.

K. Fischer, P. Cramer, R. Busch, S. Böttcher, J. Bahlo et al., Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group, J Clin Oncol Off J Am Soc Clin Oncol, vol.30, pp.3209-3225, 2012.

E. Bouvet, C. Borel, L. Obéric, G. Compaci, B. Cazin et al., Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia, Haematologica, vol.98, pp.65-70, 2013.

M. Hallek, B. D. Cheson, D. Catovsky, F. Caligaris-cappio, G. Dighiero et al., Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-working group 1996 guidelines, Blood, vol.111, pp.5446-56, 2008.

M. Hallek, B. D. Cheson, D. Catovsky, F. Caligaris-cappio, G. Dighiero et al., iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL, Blood, vol.131, pp.2745-60, 2018.

S. Boettcher, M. Ritgen, K. Fischer, S. Stilgenbauer, R. Busch et al., Minimal residual disease (MRD) re-growth kinetics are an independent predictor for progression free survival (PFS) in chronic lymphocytic leukemia (CLL) and are related to biologically defined CLLsubgroups-results from the CLL8 trial of the German CLL study group (GCLLSG), Blood, vol.118, pp.1777-1784, 2011.

D. Bagnara, M. S. Kaufman, C. Calissano, S. Marsilio, P. Patten et al., A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease, Blood, vol.117, pp.5463-72, 2011.

C. S. Tam, S. O'brien, W. Wierda, H. Kantarjian, S. Wen et al., Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia, Blood, vol.112, pp.975-80, 2008.

A. C. Rawstron, N. Villamor, M. Ritgen, S. Böttcher, P. Ghia et al., International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia, Leukemia, vol.21, pp.956-64, 2007.

A. C. Rawstron, S. Böttcher, R. Letestu, N. Villamor, C. Fazi et al., Improving efficiency and sensitivity: European research initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL, Leukemia, vol.27, pp.142-151, 2013.

A. C. Rawstron, C. Fazi, A. Agathangelidis, N. Villamor, R. Letestu et al., A complementary role of multiparameter flow cytometry and highthroughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European research initiative on CLL study, Leukemia, vol.30, pp.929-965, 2016.

B. Eichhorst, A. Fink, J. Bahlo, R. Busch, G. Kovacs et al., First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial, Lancet Oncol, vol.17, pp.928-970, 2016.

J. Maertens, S. Cesaro, G. Maschmeyer, H. Einsele, J. P. Donnelly et al., ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients, J Antimicrob Chemother, vol.71, pp.2397-404, 2016.
URL : https://hal.archives-ouvertes.fr/pasteur-01405235

J. Phair, A. Muñoz, R. Detels, R. Kaslow, C. Rinaldo et al., The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS cohort study group, N Engl J Med, vol.322, pp.161-166, 1990.

A. M. Fink, J. Bahlo, R. Sandra, O. Al-sawaf, A. Aldaoud et al., Lenalidomide maintenance after front line therapy substantially prolongs progression free survival in high risk CLL: interim results of a phase 3 study (CLL M1 study of the German CLL study group), Blood, vol.128, pp.229-238, 2016.

A. A. Chanan-khan, A. Zaritskey, M. Egyed, S. Vokurka, S. Semochkin et al., Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, Lancet Haematol, vol.4, pp.534-577, 2017.

T. D. Shanafelt, A. G. Ramsay, C. S. Zent, J. F. Leis, H. W. Tun et al., Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL), Blood, vol.121, pp.4137-4178, 2013.

A. G. Ramsay, A. J. Clear, R. Fatah, and J. G. Gribben, Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer, Blood, vol.120, pp.1412-1433, 2012.

A. P. Kater, S. H. Tonino, A. Egle, and A. G. Ramsay, How does lenalidomide target the chronic lymphocytic leukemia microenvironment?, Blood, vol.124, pp.2184-2193, 2014.

P. Strati, M. J. Keating, J. A. Burger, S. M. O'brien, W. G. Wierda et al., Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia, Haematologica, vol.102, pp.494-500, 2017.

J. A. Dubovsky, K. A. Beckwith, G. Natarajan, J. A. Woyach, S. Jaglowski et al., Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes, Blood, vol.122, pp.2539-2588, 2013.

C. U. Niemann, S. Herman, I. Maric, J. Gomez-rodriguez, A. Biancotto et al., Disruption of in vivo chronic lymphocytic leukemia tumormicroenvironment interactions by Ibrutinib--findings from an investigatorinitiated phase II study, Clin Cancer Res Off J Am Assoc Cancer Res, vol.22, pp.1572-82, 2016.

M. Podhorecka, A. Goracy, A. Szymczyk, M. Kowal, B. Ibanez et al., Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number, Oncotarget, vol.8, pp.34661-34670, 2017.

M. Long, K. Beckwith, P. Do, B. L. Mundy, A. Gordon et al., Ibrutinib treatment improves T cell number and function in CLL patients, J Clin Invest, vol.127, pp.3052-64, 2017.

L. Ysebaert, E. Gross, E. Kühlein, A. Blanc, J. Corre et al., Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in Bchronic lymphocytic leukemia: implication for maintenance immunotherapy, Leukemia, vol.24, pp.1310-1316, 2010.

D. Lad, R. Hoeppli, Q. Huang, R. Garcia, L. Xu et al., Regulatory T-cells drive immune dysfunction in CLL, Leuk Lymphoma, vol.2017, pp.1-4

A. Rissiek, C. Schulze, U. Bacher, A. Schieferdecker, B. Thiele et al., Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia, Int J Cancer, vol.135, pp.2370-2379, 2014.

V. E. Mpakou, H. Ioannidou, E. Konsta, M. Vikentiou, A. Spathis et al., Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia, Leuk Res, vol.60, pp.74-81, 2017.

E. Joffe, A. Arad, N. Bairey, O. Fineman, R. Ruchlemer et al., Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival, Hematol Oncol, vol.36, pp.128-163, 2018.

T. D. Shanafelt, V. Wang, N. E. Kay, C. A. Hanson, S. M. O'brien et al., A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912), Blood, vol.132, issue.1, 2018.

P. Strati, M. J. Keating, S. M. O'brien, J. Burger, A. Ferrajoli et al., Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL, Blood, vol.123, pp.3727-3759, 2014.

D. T. Smallwood, B. Apollonio, S. Willimott, L. Lezina, A. Alharthi et al., Extracellular vesicles released by CD40/IL-4-stimulated CLL cells confer altered functional properties to CD4+ T cells, Blood, vol.128, pp.542-52, 2016.

M. M. Aguilar-hernandez, M. D. Blunt, R. Dobson, A. Yeomans, S. Thirdborough et al., IL-4 enhances expression and function of surface IgM in CLL cells, Blood, vol.127, pp.3015-3040, 2016.

W. Wang, H. Zhu, Y. Wu, Y. Xia, J. Wu et al., Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia, J Cancer Res Clin Oncol, vol.144, pp.449-57, 2018.

, Publisher's Note

, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations